<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02349906</url>
  </required_header>
  <id_info>
    <org_study_id>MC-FludT.16/NM</org_study_id>
    <nct_id>NCT02349906</nct_id>
  </id_info>
  <brief_title>Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases</brief_title>
  <official_title>Clinical Phase II Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Paediatric Patients With Non-malignant Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Therametrics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>INC Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>medac GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to describe the safety and efficacy of intravenous (i.v.) Treosulfan
      compared to the conventional (myeloablative) dose of i.v. Busulfan, each administered as part
      of a standardised Fludarabine-containing conditioning regimen and to contribute to a PK model
      which permits - in conjunction with data comparing Treosulfan and Busulfan in adults with
      malignant diseases - to extend the use of Treosulfan in the paediatric population by
      extrapolating efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prospective clinical phase II protocol MC-FludT.16/NM is to be conducted to verify safety
      and efficacy of Treosulfan-based conditioning compared to Busulfan-based conditioning in
      paediatric patients. Based on the given clinical experience with either Treosulfan-based or
      Busulfan-based conditioning in combination with Fludarabine no increased risk for graft
      failure is expected in paediatric patients. A potential benefit for study patients is
      expected with respect to a probably low non-haematological toxicity of treatment compared to
      myeloablative TBI-based conditioning or high-dose Busulfan-based conditioning in combination
      with Cyclophosphamide.

      However, the allogeneic HSCT procedure itself potentially involves serious risks with regard
      to severe or life-threatening conditions like graft versus host disease (GvHD) and/or
      infectious complications as well as graft failure.

      In summary, the primary goal of this study is to evaluate the Treosulfan-based myeloablative
      conditioning regimen as an alternative in children and to contribute to the current PK model
      for Treosulfan to be able to finally give age (or body surface area [BSA]) dependent dose
      recommendations. The treatment regimens given in the protocol MC-FludT.16/NM are based on
      sufficient clinical safety and efficacy data. Considering the vital indication for allogeneic
      HSCT of the selected patient population, the risk-benefit assessment seems to be in favour of
      the study conduct.

      Moreover, planned interim analyses will ensure the early identification of unexpected risks.
      Therefore, the conduct of the protocol MC-FludT.16/NM is considered reasonably justified.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparative evaluation of freedom from transplant (treatment)-related mortality (TRM), defined as death from any transplant-related cause from the day of first administration of study medication (day -7) until day +100 after HSCT.</measure>
    <time_frame>day -7 to day +100</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Primary Immunodeficiencies</condition>
  <condition>Inborn Errors of Metabolism</condition>
  <condition>Haemoglobinopathies</condition>
  <condition>Bone Marrow Failure Syndromes</condition>
  <arm_group>
    <arm_group_label>Treosulfan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One Treosulfan dose per day (10, 12 or 14 g/m2/day, based on body surface area) administered i.v. on three consecutive days (-6, -5 and -4); given over 2 hours as part of background conditioning regimen prior to allogeneic stem cell transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Busulfan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Total daily Busilvex dose (3.2 to 4.8 mg/kg/day, based on body weight) according to authorised dosage for children and adolescents administered i.v. as part of the background conditioning regimen on four consecutive days (days -7, -6, -5 and -4); given in 1, 2, or 4 portions per day according to the respective hospital's standard.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treosulfan</intervention_name>
    <arm_group_label>Treosulfan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busilvex</intervention_name>
    <arm_group_label>Busulfan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Non-malignant disease indicated for first myeloablative allogeneic HSCT, including
             inborn errors of metabolism, primary immunodeficiencies, haemoglobinopathies and bone
             marrow failure syndromes.

          2. First allogeneic HSCT.

          3. Available matched sibling donor (MSD), matched family donor (MFD) or matched unrelated
             donor (MUD). For bone marrow (BM) and peripheral blood (PB) match is defined as at
             least 9/10 allele matches after four digit typing in human leucocyte antigen (HLA)-A,
             -B, -C, -DRB1 and DQB1 antigens. For umbilical cord blood (UCB) match is defined as at
             least 5/6 matches after two digit typing in HLA-A and -B and four digit typing in DRB1
             antigens.

        Exclusion Criteria:

          1. Second or later HSCT.

          2. HSCT from mismatched donor (less than 9/10 BM/peripheral blood stem cells (PBSC) or
             less than 5/6 matched cord donor).

          3. Preterm newborn infants (&lt;37 weeks gestational age) and term newborn infants aged 0 -
             27 days at time of registration.

          4. Obese paediatric patients with body mass index weight (kg)/[height (m)]² &gt; 30 kg/m².

          5. Diagnosis of Fanconi anaemia and other chromosomal breakage disorders,
             radiosensitivity disorders (deoxyribonucleic acid (DNA) Ligase 4, Cernunnos- X-ray
             repair cross-complementing protein 4 (XRCC4) like factor (XLF), Nijmegen Breakage
             Syndrome (NBS)) and Dyskeratosis Congenita.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl-Walter Sykora, MD and Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jochen Kehne, PhD</last_name>
    <phone>0049/41038006</phone>
    <phone_ext>388</phone_ext>
    <email>j.kehne@medac.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kay-Uwe Heuer</last_name>
    <phone>0049/41038006</phone>
    <phone_ext>8217</phone_ext>
    <email>k.heuer@medac.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Anna Children's Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Motol, Dep. of Paediatric Haematology and Oncology</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Sedlacek, MD, Prof.</last_name>
      <phone>+42060672</phone>
      <phone_ext>6550</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duesseldorf University Hospital</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roland Meisel, MD, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Bader, MD, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ingo Mueller, MD, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hannover Medical University, Dep. of Paediatrics, Paediatric Haematology and Oncology</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl-Walter Sykora, MD, Prof.</last_name>
      <phone>+49(0)511532</phone>
      <phone_ext>5830</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heidelberg University Hospital</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johann Greil, MD, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Horpital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Selim Corbacioglu, MD, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ulm, University Hospital, Clinic for Children and Adolescents</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ansgar Schulz, MD, Prof.</last_name>
      <phone>+49(0)731500</phone>
      <phone_ext>57154</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul-Gerhardt Schlegel, MD, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Bambino Gesu Roma</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Locatelli, MD, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita Torino</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franca Fagioli, MD, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki im. dr Antoniego Jurasza</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-094</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Styczynski, MD, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Dzieciecy w Krakowie</name>
      <address>
        <city>Krakow</city>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jolanta Gozdzik, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dzieciecy Szpital Kliniczny im. A. Gebali w Lublinie</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katarzyna Drabko, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wroclaw Medical University, Department of Pediatric Hematology/Oncology and BMT</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krzysztof Kałwak, MD, PhD, Prof.</last_name>
      <phone>(48)-71</phone>
      <phone_ext>7703170</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2015</study_first_submitted>
  <study_first_submitted_qc>January 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2015</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-malignant diseases, allogeneic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
    <mesh_term>Hemoglobinopathies</mesh_term>
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Treosulfan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

